Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
₹1 Cr
Revenue (TTM)
₹-- Cr
Net Profit (TTM)
₹0 Cr
ROE
-1.2 %
ROCE
-0.6 %
P/E Ratio
--
P/B Ratio
0
Industry P/E
378.98
EV/EBITDA
-678
Div. Yield
0 %
Debt to Equity
1.2
Book Value
₹--
EPS
₹-0.2
Face value
10
Shares outstanding
8,200,000
CFO
₹-11.68 Cr
EBITDA
₹-13.47 Cr
Net Profit
₹-16.22 Cr
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
ABL Biotechnologies
| -- | -- | 1.7 | -47.1 | -38.1 | -37.9 | -33.1 |
|
BSE Sensex*
| -13.4 | -9.8 | -13.9 | -3.6 | 7.5 | 7.9 | 11.2 |
|
BSE Healthcare#
| -4.7 | -5.8 | -5.4 | 1.3 | 23.7 | 14.0 | 10.6 |
|
Company
|
2014
|
|---|---|
|
ABL Biotechnologies
| -54.0 |
|
BSE Sensex
| 29.9 |
|
BSE Healthcare
| 47.4 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price (₹) | Market Cap (₹ Cr) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
ABL Biotechnologies
|
0.8 | 0.7 | -- | -0.1 | -- | -- | -- | 0.0 |
| 16.8 | 72.6 | 44.6 | -16.6 | -- | 0 | -- | -- | |
| 147.5 | 2,311.0 | 2,796.8 | 118.8 | 8.1 | 2.3 | 19.5 | 0.4 | |
| 24.0 | 7.3 | 0.5 | 0.0 | 8.3 | -1.1 | -- | 1.9 | |
| 472.6 | 11,419.1 | 3,262.7 | 439.0 | 15.3 | 16 | 26 | 3.8 | |
| 55.5 | 196.5 | 133.8 | -0.3 | -0.7 | -0.6 | -- | 1.9 | |
| 960.0 | 20,343.5 | 2,169.9 | 332.9 | 20.9 | 15.4 | 61.1 | 8.6 | |
| 4,578.1 | 10,524.2 | 878.4 | 240.1 | 33.8 | 73.3 | 43.8 | 27.4 | |
| 41.2 | 609.8 | 0.0 | 1.6 | -- | -0.5 | 379 | 22.7 | |
| 24.2 | 53.8 | 51.4 | 4.5 | 22.0 | 5.2 | 11.9 | 0.6 |
No Review & Analysis are available.
Manufacture of allopathic pharmaceutical preparations
Incorporated
1992
Chairman
K O Isaac
Managing Director
K O Isaac
Headquarters
Chennai, Tamil Nadu
Website
Our rating system has guided millions of investors in the past 20 years.
Annual Reports
Announcements
View AnnouncementsLimited Review Report for June 30, 2016
21-Oct-2016Board Meeting Intimation for Results
21-Oct-2016Standalone Financial Results for June 30, 2016
17-Aug-2016Board Meeting on August 13, 2016
28-Jul-2016
The share price of ABL Biotechnologies Ltd is ₹0.81 (BSE) as of 11-Jul-2016 IST. ABL Biotechnologies Ltd has given a return of -38.11% in the last 3 years.
Since, TTM earnings of ABL Biotechnologies Ltd is negative, P/E ratio is not available.
The P/B ratio of ABL Biotechnologies Ltd is 0.05 times as on 11-Jul-2016, a 97 discount to its peers’ median range of 1.86 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2012
|
0.00
|
0.28
|
|
2011
|
0.00
|
0.50
|
|
2010
|
0.00
|
1.07
|
|
2009
|
0.00
|
0.28
|
|
2008
|
16.00
|
3.35
|
The 52-week high and low of ABL Biotechnologies Ltd are Rs -- and Rs -- as of 03-Apr-2026.
ABL Biotechnologies Ltd has a market capitalisation of ₹ 1 Cr as on 11-Jul-2016. As per SEBI classification, it is a company.
Before investing in ABL Biotechnologies Ltd, assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
₹0.02
(
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.